Physician

Manuel Salas Cunanan, M.D.

According to 2025 Medicare claims, Manuel Cunanan, M.D. (NPI: 1144474636) practices pulmonary disease in the Vineland, NJ market, with the plurality of this provider's patient population coming from Cumberland, NJ. This provider's primary affiliated billing organization is PULMONARY HEALTH CONSULTANTS, LLC (NPI: 1871962787; TIN: 474754995) and primary practice location at 08332-2532.

Cunanan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 694 traditional Medicare patients, billed 3,741 HCPCS/CPT codes, and received $220,623 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,806 prescription claims across 692 beneficiaries totaling $2,744,974 in drug costs, led by Fasenra (Benralizumab). DME data shows 3,404 claims. Open Payments data shows 325 records totaling $153,659. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $184,458 and ending at $220,623. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $86,653 to $2,744,974. For DME billing, reported payments rose steadily, from $43,256 to $212,403.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	782	2,996	$184,458
2016	910	3,704	$232,983
2017	862	3,170	$230,342
2018	770	3,632	$231,929
2019	420	2,302	$147,567
2020	449	3,458	$221,926
2021	641	4,110	$283,568
2022	598	3,404	$219,342
2023	667	4,542	$281,999
2024	694	3,741	$220,623

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	167	372	$86,653
2016	196	803	$231,033
2017	257	1,308	$402,405
2018	368	2,048	$643,981
2019	367	1,741	$794,040
2020	412	3,101	$1,648,524
2021	537	3,789	$1,527,019
2022	559	3,111	$1,583,203
2023	666	3,552	$2,519,512
2024	692	3,806	$2,744,974

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	251	701	$44,684
2016	539	1,646	$87,308
2017	676	2,040	$115,293
2018	871	2,704	$182,310
2019	876	2,500	$156,285
2020	1,044	3,160	$301,171
2021	1,280	4,008	$488,880
2022	1,270	3,699	$347,806
2023	1,225	3,564	$396,052
2024	1,248	3,404	$314,324

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	438	770	$98
94729	Test to examine how well the lungs exchange gases	439	516	$51
94727	Test to determine lung volumes using gas dilution or washout	439	516	$40
94060	Test to measure expiratory airflow and volume changes before and after medication administration	432	504	$34
94618	Test for exercise-induced lung stress	450	532	$29

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Fasenra	Benralizumab	68	3,080	$382,308
Tezspire	Tezepelumab-Ekko	86	2,408	$371,797
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	399	15,960	$321,928
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	366	14,610	$304,889
Dupixent Pen	Dupilumab	64	1,710	$240,412

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7677	Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram	N	21	94	$73,668
E0483	High frequency chest wall oscillation system, with full anterior and/or posterior thoracic region receiving simultaneous external oscillation, includes all accessories and supplies, each	Y	15	74	$69,860
E0466	Home ventilator, any type, used with non-invasive interface, (e.g., mask, chest shell)	Y	N/R	34	$34,490
J7606	Formoterol fumarate, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 20 micrograms	N	18	88	$17,025
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	35	225	$15,156

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	325	$153,659	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Manuel Salas Cunanan, M.D.?

Tedicare shows public-source Medicare data for Manuel Salas Cunanan, M.D. (NPI 1144474636), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Manuel Salas Cunanan, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Manuel Salas Cunanan, M.D.?

Manuel Salas Cunanan, M.D. is linked to PULMONARY HEALTH CONSULTANTS, LLC (billing NPI 1871962787) in the available physician profile data.

Does Manuel Salas Cunanan, M.D. have Open Payments data?

Manuel Salas Cunanan, M.D. has 325 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.